London Tech Week 2022 is part of the Informa Tech Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

London Tech Week 2022
13 - 15 June 2022
Queen Elizabeth Centre II

Christopher McCann
Co-Founder & CEO at Current Health


Christopher McCann is the CEO and Co-Founder of Current Health. During his time as a medical school student, Christopher saw an opportunity to make a broader impact in the healthcare field by using technology to address systemic issues plaguing population health – those primarily being provider resource and talent constraints that have propelled reactive, versus proactive, care delivery models.

Christopher founded Current Health in 2015 with co-founder and CTO Stewart Whiting. Their mission was to use AI-enabled Remote Patient Monitoring (RPM) technology to empower healthcare providers to continuously monitor patients (including those with chronic disease) outside the hospital. As a result, they could proactively identify and manage potential patient issues and ensure better care at scale.

Christopher’s vision for more proactive care delivery has resonated with leading providers and healthcare industry stakeholders around the world. In the last year, Current Health has grown its customer base by over 300% and counts more than 40 hospital systems as customers.

As the company has grown, and as its RPM platform collects more patient’ vital sign data, Christopher and the Current Health team have expanded how they can use RPM technology to enhance patient care. By collaborating with pharmaceutical companies and medical centers, Current Health can accelerate clinical trials and paths to treatment for chronic and critical diseases, like COVID-19. By collecting and analyzing patient data at scale, Current Health not only enables organizations to more quickly discern the correlation of disease with different biometric profiles, but also ensures the ongoing safety and wellbeing of clinical trial participants when undergoing potential treatments.

Agenda Sessions

  • The Future of Investing in HealthTech